Argenx Se (ARGX) Long-Term Deferred Tax (2016 - 2026)
Argenx Se's (ARGX) quarterly Long-Term Deferred Tax came in at $1.4 billion in Q2 2026, down 99.84% YoY from $899.6 billion in Q2 2025, and up 10.26% on a QoQ basis from $1.3 billion in Q4 2025.
Argenx Se (ARGX) Long-Term Deferred Tax (2016 - 2026) Analysis & Trends
Argenx Se (ARGX) has 11 years of Long-Term Deferred Tax data on file, last reported at $1.4 billion in Q2 2026.
- Quarterly Long-Term Deferred Tax fell 99.84% year-over-year to $1.4 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $1.4 billion (down 99.84% YoY) and the FY2025 annual result came in at $1.3 billion, up 40.21% from the prior year.
- Long-Term Deferred Tax improved to $1.4 billion in Q2 2026, from $1.3 billion in the prior quarter.
- In the past five years, Long-Term Deferred Tax ranged from a high of $899.6 billion in Q2 2025 to a low of $54.3 million in Q2 2022.
- A 5-year average of $100.4 billion and a median of $174.6 million in 2024 frame the typical range for Long-Term Deferred Tax.
- Annual changes were most pronounced in 2025 — Long-Term Deferred Tax jumped 515062.12% — and 2026, when it plunged 99.84%.
- Tracing ARGX's Long-Term Deferred Tax over 5 years: stood at $79.2 million in 2022, then rose by 22.71% to $97.2 million in 2023, then soared by 850.82% to $924.3 million in 2024, then jumped by 40.21% to $1.3 billion in 2025, then grew by 10.26% to $1.4 billion in 2026.
- The last three Long-Term Deferred Tax figures came in at $1.4 billion (Q2 2026), $1.3 billion (Q4 2025), and $899.6 billion (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.43 Bn |
| Dec 31, 2025 | 1.30 Bn |
| Jun 30, 2025 | 899.61 Bn |
| Dec 31, 2024 | 924.30 Mn |
| Jun 30, 2024 | 174.63 Mn |
| Dec 31, 2023 | 97.21 Mn |
| Jun 30, 2023 | 138.77 Mn |
| Dec 31, 2022 | 79.22 Mn |
| Jun 30, 2022 | 54.27 Mn |
| Dec 31, 2021 | 32.19 Mn |
| Jun 30, 2021 | 16.25 Mn |
| Dec 31, 2020 | 14.61 Mn |
| Dec 31, 2019 | 44.28 Mn |
| Dec 31, 2018 | 33.44 Mn |
| Dec 31, 2017 | 33.44 Mn |
| Dec 31, 2016 | 22.67 Mn |